Table 4.
Effect of siRNA mediated knockdown of selected genes on cytarabine sensitivity in THP1 cells.
| Gene symbol | PROMISE analysis | siRNA-drug modifier GENE LEVEL effect-Based on RSA ranking | siRNA-drug modifier GENE LEVEL effect-Based on threshold (at least 2 siRNAs passing threshold) | Non-neutral genes refer to genes, which do yield a detectible RNAi phenotype in the absence of the drug (phenotype was sometimes further enhanced post-drug treatment) | Only one of three siRNA influence drug response |
|---|---|---|---|---|---|
| ADRBK1 | PR3 | Increased cytarabine resistance | Increased cytarabine resistance | ||
| APOBEC2 | PR2 and PR3 | Increased sensitivity | |||
| APOBEC3G | PR2 and PR3 | Increased cytarabine sensitivity | non-neutral | ||
| CHI3L1 | PR2 | Increased cytarabine sensitivity | |||
| CYLC1 | PR2 | Increased resistance | |||
| DCK | +ve control | Increased cytarabine resistance | Increased cytarabine resistance | ||
| DOCK6 | PR2 and PR3 | Increased cytarabine sensitivity | |||
| ENDOD1 | PR2 and PR3 | Increased resistance | |||
| GDF3 | PR2 | ||||
| GSTA1 | PR2 | Increased resistance | |||
| KLK13 | PR2 | ||||
| LRRTM4 | PR2 | Increased resistance | |||
| MARK1 | PR3 | ||||
| MLNR | PR2 | ||||
| NFKB2 | PR2 | Increased cytarabine sensitivity | |||
| NPAS3 | PR2 | Increased cytarabine resistance | non-neutral | Increased resistance | |
| QKI | PR3 | ||||
| RANBP1 | PR2 | ||||
| REPIN1 | PR3 | Increased cytarabine sensitivity | Increased cytarabine sensitivity | ||
| RUNX2 | PR2 | Increased resistance | |||
| SCARB1 | PR2 | Increased cytarabine resistance | Increased cytarabine resistance | ||
| SET | PR3 | non-neutral | |||
| TIGD6 | PR2 | Increased cytarabine resistance | Increased cytarabine resistance | ||
| TNC | PR2 | Increased cytarabine resistance | |||
| TRIM33 | PR2 and PR3 | non-neutral |